Balanced news tone
News Sentiment
EBS sentiment intelligence
Emergent Biosolutions Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-2.8% over one week, -3.2% over four weeks, trend inactive, and near fair-value range.
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 04:39
- Source
- Stocktwits
Emergent BioSolutions (EBS) SVP sells 3,000 shares under plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 07:00
- Source
- Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
Emergent Gets $52.7 Million Contract Modification From US Government
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 29 Jun 2026 14:31
- Source
- MT Newswires
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 29 Jun 2026 13:13
- Source
- GlobeNewswire
Emergent BioSolutions (NYSE: EBS) lands $52.7M U.S. ACAM2000 contract
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 29 Jun 2026 07:00
- Source
- Stock Titan
Emergent BioSolutions Stock (US29089Q1058): Earnings Picture And Balance Sheet Under The Microscope
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 16 Jun 2026 16:18
- Source
- Ad Hoc News
Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- Stock Titan
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 12:02
- Source
- GlobeNewswire
Emergent BioSolutions Wins $64.5 Million US Government Contract Modification for BAT
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 28 May 2026 21:31
- Source
- MT Newswires
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 28 May 2026 20:01
- Source
- GlobeNewswire
U.S. health agency awards $64.5M botulism antitoxin deal to Emergent
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 28 May 2026 07:00
- Source
- Stock Titan
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 20 May 2026 20:43
- Source
- Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 11:30
- Source
- GlobeNewswire
Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 07:00
- Source
- Stock Titan
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for Smallpox, Mpox Vaccine
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 18 May 2026 13:21
- Source
- MT Newswires
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 18 May 2026 12:59
- Source
- GlobeNewswire
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Stock Titan
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 May 2026 14:29
- Source
- MarketBeat
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 May 2026 07:00
- Source
- simplywall.st
Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- Quiver Quantitative
How The Emerging Narrative On Emergent BioSolutions (EBS) Is Shifting After The Earnings Miss
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 23 Apr 2026 07:00
- Source
- Market source
Emergent cuts loan costs and pushes debt maturities to 2031
- Tone
- Negative 34/100
- Event
- Balance sheet
- Published
- 16 Apr 2026 07:00
- Source
- Stock Titan
How The Reset Price Target Is Shaping The Emergent BioSolutions (EBS) Investment Story
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 25 Mar 2026 07:00
- Source
- Market source
How The Investment Narrative For Emergent BioSolutions (EBS) Is Shifting After The $12 Target Reset
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 10 Mar 2026 07:00
- Source
- Market source
Emergent BioSolutions Inc (EBS) Stock Price Today: $7.50
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Feb 2026 06:35
- Source
- Gotrade
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 14 Jan 2026 08:00
- Source
- simplywall.st
Institutional investors have a lot riding on Emergent BioSolutions Inc. (NYSE:EBS) with 73% ownership
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Dec 2025 08:00
- Source
- simplywall.st
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
- Tone
- Negative 34/100
- Event
- Balance sheet
- Published
- 27 Nov 2025 08:00
- Source
- simplywall.st
Emergent BioSolutions (EBS): Evaluating Valuation After Raised 2025 Guidance and Strong Q3 Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 02 Nov 2025 07:00
- Source
- simplywall.st